Here's What Markets Have Missed By Overlooking The VBI Vaccines CMV News

During the middle of last month, VBI Vaccines, Inc. (VBIV) announced a phase 3 clinical program for its lead hepatitis B asset, Sci-B-Vac. The program, and perhaps rightly so, is picking up a considerable amount of attention and VBI now has a clear path to commercialization in three major markets for the vaccine in question. Shortly after its releasing of the details for this program, however, the company also released news related to the ongoing development of one of its deeper pipeline assets. Perhaps because of the impact of the Sci-B-Vac news, markets seem to have overlooked the latter release.

Here is a look at what was missed and what it might mean for VBI and its shareholders going forward.

The release details interim data from a phase 1 study of a preventative cytomegalovirus (CMV) vaccine. For those not familiar with this company, VBI has developed a technology called the enveloped Virus like Particle (eVLP) platform. The platform is designed to allow for the creation of a new generation of vaccines; vaccines that seek to improve on the immunogenicity of current standard of care options or that aim to serve as a preventative option in areas of healthcare for which there currently exists no alternative treatment. They seek to achieve this by mimicking as closely as possible the virus against which they are trying to protect the individual being dosed.

With its eVLP platform, VBI is able to achieve this goal through a couple of different avenues. First, and primarily, the vaccines that the platform creates express numerous antigens associated with the target virus. The more antigens that are present, the more the vaccine looks like the virus to the immune system and the more antibodies the immune system creates that will then target the virus on infection. Second, the virus is constructed using mammalian cells as opposed to the plant cells used to construct many current standard of care vaccines. The mammalian nature of the vaccine, just as with the multiple antigen approach, serves to increase the similarity between a virally infected host cell and the preventative vaccine that VBI has created and with which patients are treated.

1 2 3
View single page >> |

Disclosure: The author holds no positions in any of the stocks mentioned in this piece. 

Opinions are my own and I have no business relationship with/am not receiving compensation from any ...

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
Kate Hayden 3 years ago Contributor's comment

I thought the news you were going to discuss was the IND issued today for 1901, the brain cancer program. What do you think about that newer news?

David Lamoureux 3 years ago Member's comment

Sci-B-Vac has been in my news feed for a while. I remember the first time I heard of it was at a cocktail party last year. What surprises me is that $VBIV has made remarkable progress on this drug. I think I need to pay it forward and tell my friends about its coming clinic trials this year.

Anastasija Janevska 3 years ago Member's comment

What'd you hear about them? Any insider tips? ;-) $VBIV